Anti-PCNA antibodies in psoriatic arthritis: a case-control study.

Rebecca Fitzpatrick, Jemima Albayda, Qingyuan Yang, Ning Meng, Livia Casciola-Rosen, Ana-Maria Orbai

Abstract read

In one paragraph

Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca FitzpatrickDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-0913-8503

Jemima AlbaydaDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-8030-9504

Qingyuan YangDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Ning MengDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0009-0003-0081-8697

Livia Casciola-RosenDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-4172-1539

Ana-Maria OrbaiDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-8644-8567

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026

$8.9M

NIAMS NIH HHS P30 AR070254

6 · The paper itself

Abstract

Objectives: Psoritic arthritis (PsA) is an inflammatory arthritis with infrequent antibodies. We present a case-control study of six PsA patients with antibodies against PCNA and observed clinical associations. Methods: We conducted a study to identify autoantibodies in PsA. Sera from 81 PsA patients were assayed by immunoprecipitation from radiolabelled cell extracts. From this study, serum that immunoprecipitated a ≈32-kDa band was selected for mass spectrometry-based antibody discovery, which identified anti-PCNA antibodies. These were validated using immunoprecipitation of Results: Anti-PCNA antibodies were identified in 6/222 PsA patients. In 4/6 patients, banked longitudinal sera were available. In patients with anti-PCNA positivity compared with negativity, the mean age was 46 years (s.d. 14) and 52 years (s.d. 13), PsA disease duration was 8 years (s.d. 7) and 7 years (s.d. 8), BMI was 27 (s.d. 4) and 31 (s.d. 7), 67% and 44% were male, 100% and 89% were White, mean clinical DAPSA was 16 (s.d. 22) and 21 (s.d. 16), psoriasis body surface area was 2% (s.d. 4) and 5% (s.d. 12), HLA-B27 positivity was 0 and 12% and sulfasalazine (SSZ) use was 83% and 10%, respectively. Of these, only SSZ use was significant (Fisher's exact test Conclusion: Anti-PCNA antibodies were found in 6/222 (2.7%) PsA patients. Given the low prevalence of anti-PCNA, additional studies are needed to identify the clinical associations and significance.

Indexed as

antibodiesanti-PCNApsoriasispsoriatic arthritis

Identifiers

PMID40417241

DOI10.1093/rap/rkaf049

PMCPMC12103914

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.